Ambitions for Checkpoint Therapeutics' EGFR inhibitor

13 August 2018
2019_biotech_test_vial_discovery_big

There has been a steady drumbeat of failure in the race to develop a third-generation EGFR inhibitor to compete with Tagrisso(osimertinib) from AstraZeneca (LSE: AZN) in an around $5 billion market.

Now Checkpoint Therapeutics, a Fortress Biotech (Nasdaq: FBIO) company, is gaining visibility. Checkpoint announced today that Phase I/II data from its third-generation EGFR inhibitor CK-101 has been selected for a late-breaking oral presentation at the International Association for the Study of Lung Cancer’s 19th World Conference on Lung Cancer, to be held September 23-26.

Other Big Pharmas have tried their hand at a third-generation therapy, but all real competition has failed:

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology